// App-Quantinova.ai

3571 : Preclinical Evaluation of Oncolytic Reovirus in Targeted Therapeutics for High-Risk Pediatric Leukemia

Researchers

Presenter

  • Aru Narendran

Principal Investigators

  • Erwin T Cabacungan

  • Randal N. Johnston

Medical Centers

  • Southern Alberta Cancer Research Institute, University of Calgary, Calgary, AB, Canada

  • Biochemistry and Molecular Biology, Southern Alberta Cancer Research Institute, University of Calgary, Calgary, AB, Canada

Locations

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Endocrine/metabolic Diseases (ME)

Disease

  • Cardiotoxicity

  • Solid malignancies

  • Infertility

  • Obesity

Biomarkers

  • B-cell lymphoma 2

  • Histone-lysine N-methyltransferase 2A

Drug/Treatment

  • Pelareorep

  • ABT-737

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved